Researchers have used lab technology called mass spectrometry to study the proteins expressed by human cancer cells. The advance, which is described in a new Molecular Oncology article, allows for the quantitation of thousands of tumour proteins over the course of several hours.
The adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in "on-target, off-tumor" toxicities.
Editing cells’ genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies published on Monday warn — a potential game-changer for the companies developing CRISPR-based therapies.
The immune system uses an extremely complex regulatory system to achieve the goal of effectively eradicating pathogens without causing excessive host tissue damage. A successfully coordinated immune response is dependent on secreted chemical signals (cytokines), protein–protein interactions between adjacent cells, and the activity of various enzymes that alter the microenvironment.
Women diagnosed with breast cancer by breast screening have a better survival than women with symptomatic breast cancer, even after adjustment for age, nodal status, and tumor size. Breast screening identifies many noninvasive and invasive breast cancers with a low rate of subsequent recurrence or death. Between 11% and 19% of screen-detected breast cancers are overdiagnosed, that is, that had they not been screened the patient would not have known that they had breast cancer, nor required treatment within their lifetime.
Cancer is one of the topmost killers worldwide. The complexity and wide variety of types makes it hard to find one useful therapy to neutralize it, without harming healthy tissue. Now, researchers at The Scripps Research Institute in Florida think they’ve developed one. Their report was published in The Proceedings of the National Academy of Sciences (PNAS). It all surrounds immunotherapy.
Two years ago, this was a "pipe dream" but "today, we actually have data to show this is really feasible to find early-stage cancer in the blood," said lead investigator Geoffrey R. Oxnard, MD, associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.